MilliporeSigma now offers complete and fully integrated services and products for the development and manufacturing of antibody-drug conjugates (ADCs) from gene sequencing to final drug substance. Products and services include process development and manufacturing of monoclonal antibodies, linker and payload supply, and conjugation expertise. A streamlined supply chain for raw materials, industry-leading global logistics expertise and a single point of contact for each project mitigates risks, reduces complexity and accelerates time to market.
MilliporeSigma’s integrated offering combines more than 30 years of experience in development and manufacturing of biologics, conjugation processes and small molecules. A seamless process from gene sequencing to stability testing of drug products enables customers to reduce development and manufacturing complexity.
Key benefits of the fully integrated ADC offering include:
While ADCs represent a promising new type of therapy, the corresponding supply chain of monoclonal antibodies, payloads, and linkers presents a significant challenge. MilliporeSigma’s new combined offering provides the capabilities, products and expertise to simplify production and accelerate time to market, while easily managing a complex supply chain.